PF-9366 / Pfizer - LARVOL DELTA

Multiplex Methionine Modulating Hydrogel for Cancer Metabolic Therapy. (PubMed, Adv Mater) - "Small molecule inhibitors PF9366 and adenosine dialdehyde are encapsulated by tumor cell-targeting nanoparticles (NPs) to achieve a cascaded blockage of intracellular methionine metabolism. These NPs are further co-loaded with the extracellular methionine uptake inhibitor JPH203 into a type of reactive oxygen species-sensitive hydrogel, assembling the multiplex methionine modulating hydrogel (3 M Gel)...Moreover, remodeling of the tumor microenvironment by 3 M Gel overcomes immune checkpoint blockade resistance in TNBC. This study presents a localized triple regulation strategy and paves a new path for amino acid starvation-based cancer therapy."

Journal • Breast Cancer • Colorectal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

MAT2A inhibition suppresses inflammation in Porphyromonas gingivalis-infected human gingival fibroblasts. (PubMed, J Oral Microbiol) - "HGFs werecultured and treated with P. gingivalis, with or without MAT2Ainhibitor (PF9366), small interference RNA (siRNA), or extrinsic SAMpretreatment...MAT2A-mediated methionine metabolism promoted P. gingivalis-inducedinflammation in hGFs. Targeting MAT2A may provide a novel therapeuticmethod for modulating periodontitis."

Journal • Dental Disorders • Infectious Disease • Inflammation • Periodontitis • MAT2A

A role for protein arginine methyltransferase 7 in repetitive and mild traumatic brain injury. (PubMed, Neurochem Int) - "In addition, in vitro inhibition of the upstream mediator MAT2A using the HT22 hippocampal neuronal cell line suggest a mechanistic role for PRMT7 via MAT2A. Collectively, we have identified PRMT7 as a novel target in rmTBI pathology in vivo and a mechanistic link between PRMT7 and upstream mediator MAT2A in vitro."

Journal • CNS Disorders • Inflammation • Vascular Neurology • MAT2A • PRMT7